Innovations in Oncology: Gastrointestinal Cancers
How could emerging data on novel immuno-oncology (IO) strategies change your approach to therapy?
This educational series examines the current role of immunotherapy in gastric cancers and explores the future direction of IO therapy in treatment. Our globally renowned experts provide an update on advances to care that you can apply to your practice today. They also review National Comprehensive Cancer Network guidelines pertaining to patients with MSI-H/dMMR or HER2+ colorectal cancer; gastric, esophageal, and gastroesophageal junction cancers; and advanced hepatocellular carcinoma.
Provided by:
In Partnership with:
Episodes 1-11 of 11
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
MinuteCE®First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
